

**DECRETO RETTORE UNIVERSITA' DI ROMA "LA SAPIENZA"**

**N 1921/2024 DEL 31/7/2024**

**CODICE CONCORSO 2024PAE004**

**CURRICULUM VITAE COSMO DEL BORGO**

**Allegato B- Ai fini della pubblicazione**

**Versione redatta in modo da garantire la conformità del medesimo a quanto prescritto dall'art. 4 del Codice in materia di protezione dei dati personali e dall'art. 26 del D. Lgs 14 marzo 2013, n33**

**Place Latina**

**Date : 22/9/2024**

**Part I General Information**

**Full Name:** Cosmo Del Borgo

**POSITION TITLE:** Director (temporary) of the Unit of Infectious Disease, Azienda Sanitaria of Latina, SM Goretti Hospital

**Part II EDUCATION/TRAINING**

| <b>TYPE</b>           | <b>Year</b> | <b>Institution</b>                                                                                                                  | <b>FIELD OF STUDY</b>                                                                |
|-----------------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| University graduation | 1985-1991   | Catholic University of the Sacred Heart, Rome                                                                                       | Medicine and Surgery                                                                 |
| Post-graduate studies | 1991-1993   | Catholic University of the Sacred Heart, Rome Department of Infectious Diseases, Catholic University, Rome, Italy                   | Virology laboratory research on HBV and HIV coinfection; CMV/HIV coinfection         |
| Post-graduate studies | 1991-1994   | Clinical training Catholic University of the Sacred Heart, Rome Department of Infectious Diseases, Catholic University, Rome, Italy | Clinical research in HIV and Infectious Diseases (Health-care associated infections) |
| Speciality            | 1996-1999   | Catholic University of Rome Department of Infectious Diseases, Catholic University, Rome, Italy                                     | Infectious Disease                                                                   |
| Master                | 2007        | Catholic University, Rome, Italy                                                                                                    | Sepsis in surgical patients                                                          |
| Master                | 2015        | Tor Vergata University, Rome, Italy                                                                                                 | Antiretroviral therapy                                                               |

|                    |             |                                                                                                                                                               |                                                                           |
|--------------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Ph.D.              | 1993-1997   | Catholic University of Rome Department of Infectious Diseases, Catholic University, Rome, Italy                                                               | Pain and symptoms in HIV disease, Quality of life research in HIV disease |
| Licensure          | 14 /12/1991 | Catholic University of Rome                                                                                                                                   | Licensure for medical clinical practice                                   |
| Foreign experience | 2004        | Clinical e research training in Palliative Care for people with AIDS, Camden and Islington, Community Health Services NHS Trust, Palliative Care Team, London | Palliative care for people with AIDS                                      |

### Part III- Appointments

#### IIIA- Academic Appointment

| Start      | End     | Institution | Position                                                           |
|------------|---------|-------------|--------------------------------------------------------------------|
| 12/12/2023 | ongoing | MIUR        | ASN-National Scientific Habilitation for Associate Professor 06/D4 |

#### IIIB Other Appointments

| Start | End     | Institution                                                                                                             | Position                                                                 |
|-------|---------|-------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| 1994  | 2002    | Catholic University of the Sacred Heart, Rome<br>Department of Infectious Diseases,<br>Catholic University, Rome, Italy | Temporary contract as MD,<br>Infectious Disease Specialist               |
| 2002  | 2005    | National Institute of Infectious Diseases,<br>Lazzaro Spallanzani, Rome                                                 | Permanent contract as MD,<br>Infectious Disease Specialist               |
| 2003  | 2005    | National Institute of Infectious Diseases,<br>Lazzaro Spallanzani, Rome                                                 | Highly professional assignment: “Flussi informative attività di reparto” |
| 2005  | Ongoing | Azienda Sanitaria of Latina, SM Goretti Hospital                                                                        | Permanent contract as MD,<br>Infectious Disease Specialist               |

|      |         |                                                  |                                                                                  |
|------|---------|--------------------------------------------------|----------------------------------------------------------------------------------|
| 2017 | 2019    | Azienda Sanitaria of Latina, SM Goretti Hospital | Highly professional assignment: “Prevention and control of nosocomial infection” |
| 2020 | 2023    | Azienda Sanitaria of Latina, SM Goretti Hospital | Director “Sepsis management program”                                             |
| 2023 | ongoing | Azienda Sanitaria of Latina, SM Goretti Hospital | Director Clinical UNIT (UOS): HIV center                                         |
| 2023 | ongoing | Azienda Sanitaria of Latina, SM Goretti Hospital | Main local referent regional program for “Antimicrobial resistance”              |
| 2024 | ongoing | Azienda Sanitaria of Latina, SM Goretti Hospital | Temporary Director of the Unit of Infectious Disease                             |

#### Part IV- Teaching experiences:

| Start | End     | Institution                               | Lecture/Course                                                                                                |
|-------|---------|-------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| 2009  | ongoing | Sapienza University (as external teacher) | Infectious disease at : <b>Corso di laurea F</b>                                                              |
| 2017  | 2024    | Catholic University of Rome               | Master in “Antibiotic stewardship” : Catholic University of Rome)                                             |
| 2021  | Ongoing | Sapienza University (as external teacher) | Infectious Disease at <b>Corso di Laurea Fisioterapia</b> (Latina)                                            |
| 2021  | Ongoing | Sapienza University (as external teacher) | Infectious Disease at <b>Corso di Laurea Terapia della neuro e psicomotricità dell’età evolutiva</b> (Latina) |
| 2021  | ONGOING | Regional school of general medicine       | Infectious Disease at : <b>Course for general practioners</b>                                                 |

**Tutoring and coordination of the scientific activities of PhD students, postgraduates and undergraduate student attending Division of Infectious Disease, AUSL Latina, S. M. Goretti Hospital ( 2009-ongoing)**

|                      |           |
|----------------------|-----------|
| <b>Undergraduate</b> | <b>38</b> |
| <b>Postgraduate</b>  | <b>12</b> |
| <b>PhD</b>           | <b>3</b>  |

**Part V- Society memberships, Awards and Honors**

|                     |                                                                                                             |
|---------------------|-------------------------------------------------------------------------------------------------------------|
| <b>Since : 2013</b> | Member of Italian Society of Infectious Disease (SIMIT)                                                     |
| <b>Since 2022</b>   | Board Member of Lazio Section Italian Society of Infectious Disease (SIMIT)                                 |
| <b>Since 2019</b>   | Member of Italian association for liver diseases (AISF)                                                     |
| <b>Since 2015</b>   | Member of CCICA, AUSL Latina                                                                                |
| <b>Since 2019</b>   | Member of European Society of Clinical microbiology and infectious diseases                                 |
| <b>Since 2018</b>   | Scientific Counselor of Board member of Medical Doctors Order . Latina                                      |
| <b>Since 2023</b>   | Member of Gruppo Italiano Stewardship Antimicrobica (GISA)                                                  |
| <b>Since 2023</b>   | Member of Hospital Group for prevention and control of nosocomial infection, S.M. Goretti, Hospital, Latina |

**Part VI Funding Information (grant as PI-investigator or I-investigator)**

| YEAR      | TITLE | PROGRAM                                                                                                                                                                                                                                                                                                                                          | GRANT VALUE  |
|-----------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| 1997-1999 | I     | Dinamiche temporali e determinanti della sopravvivenza delle persone con infezione da HIV nell'ambito del Programma nazionale di Ricerca AIDS, 1997, Istituto superiore di Sanità                                                                                                                                                                | £ 25.000.000 |
| 1997-1999 | I     | Studio di coorte multicentrico longitudinale per la valutazione dell'impatto delle variabili socio-demografiche e cliniche sulla qualità della vita salute-relata in pazienti con infezione da HIV, utilizzando un questionario MOS-HIV integrato. Programma Nazionale di ricerca sull'AIDS 1997. Istituto Superiore di Sanità                   | £ 25.000.000 |
| 2001-2002 | I     | Studio delle mutazioni nei geni codificanti per la lipoproteinlipasi (LPL), per l'apoproteina E (APO-E) e per il substrato 1 del recettore insulinico (IRS-1) come fattori di predisposizione alla dislipidemia in corso di terapia antiretrovirale altamente attiva. IV Programma Nazionale di ricerca sull'AIDS. Istituto Superiore di Sanità. | £ 25.000.000 |
| 2001-2003 | I     | "Intervento per il miglioramento della qualità della vita correlata alla salute e dell'aderenza alle                                                                                                                                                                                                                                             | £ 25.000.000 |

|           |   |                                                                                                                                                                                                                                                              |              |
|-----------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
|           |   | terapie antiretrovirali potenti in pazienti con infezione da HIV” nell’ambito del IV Programma Nazionale di Ricerca sull’AIDS 2001. Istituto Superiore di Sanità.                                                                                            |              |
| 2001-2003 | I | Trattamento dell’infezione da HCV nei pazienti con coinfezione HCV/HIV in terapia antiretrovirale potente. Tollerabilità, efficacia ed impatto sui parametri immunovirologici di diverse strategie a confronto” IV Programma Nazionale di Ricerca sull’AIDS. | £ 30.000.000 |
| 2002      | I | Nested HAART Pegasys; Ruolo del peg-interferon alfa 2° nel trattamento dell’infezione da HCV.                                                                                                                                                                | no           |
| 2016      | I | Progetto finanziamento per la ricerca di Ateneo 2016: ROBUSTNESS evaluation as a tool to identify HIV+ aviremic patients suitable for simplification of follow up                                                                                            | € 5.000      |
| 2016      | I | Fellowship Digital Health Program 2016 Doctor Apollo: il BOT entra nella pratica clinica come interfaccia medico-paziente-caregiver nella gestione a lungo termine della persona HIV +”                                                                      | € 30.000     |
| 2016      | I | Retrospective monocentric study on dalbavancin in the management of ABSSSIS in real practice” Studio monocentrico retrospettivo su dalbavancina nella                                                                                                        | € 7.000      |

|      |   |                                                                                                                                                                                                                                                                                       |          |
|------|---|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
|      |   | gestione delle ABSSSIS nella pratica clinica                                                                                                                                                                                                                                          |          |
| 2017 | I | “Attuali modelli europei di pratica clinica relativi alla gestione delle infezioni cutanee: valutare l’incidenza delle infezioni cutanee, la percentuale delle infezioni batteriche acute della cute e della struttura cutanea (ABSSSI) e la relativa gestione clinica e terapeutica” | € 6.000  |
| 2017 | I | Progetto Ateneo: Progetto Finanziamento per la in ricerca di Ateneo 2017: Innate immunity and immune activation in HIV/HCV coinfectd subjects undergoing DAA                                                                                                                          | € 5.000  |
| 2017 | I | Attuali modelli europei di pratica clinica relativi alla gestione delle infezioni cutanee: valutare l’incidenza delle infezioni cutanee, la percentuale delle infezioni batteriche acute della cute e della struttura cutanea (ABSSSI) e la relativa gestione clinica e terapeutica   | € 6.000  |
| 2019 | I | Progetto di Ateneo: Mucosal Immunity in HIV-1 infected women undergoing effective antiretroviral therapy biomarkers and clinical determinants                                                                                                                                         | € 10.000 |
| 2019 | I | Fellowship Program 2019 – ERADICHIAMOCI – Progetto di microeradicazione HCV tra gli utilizzatori di sostanze nel polo pontino                                                                                                                                                         | € 30.000 |

|      |   |                                                                                                                                                                                                  |          |
|------|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 2020 | I | TOCIVID-19 Multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. EudraCT Number                                                | no       |
| 2020 | I | Progetto Ateneo: Ruolo dell'immunità innata nell'infezione da SARS-COV2 in una coorte di pazienti con polmonite da COVID: biomarkers e correlati clinici                                         | € 10.000 |
| 2021 | I | Progetto di Ateneo 2021: Studio dei profili immunologici delle risposte immunitarie esercitate contro il virus SARS-CoV-2 e della possibile correlazione con l'evoluzione clinica della malattia | € 10.000 |
| 2022 | I | Vaccinazione anti-SARS-COV-2 nei soggetti HIVINFETTI: caratterizzazione della risposta e impatto sullo stato immunoinfiammatorio. N. protocollo RM1221816C7A7AB7<br>10.000 euro                  | € 10.000 |

## Part VII- Research Activities

| Keywords                                          | Brief description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>HIV infection epidemiology</b>                 | <p><b>At the beginning of my research activity I was involved in many studies in the field of epidemiology of HIV diseases producing several publications on this specific argument. Between 1994 and 2000 I collaborated with Lazio AIDS Surveillance Collaborative Group coordinated by dott. Giuseppe Ippolito)</b></p> <p>Porta D., Rapiti E., Forastiere F., Pezzotti P and Perucci C. A. for the Lazio AIDS Surveillance Collaborative Group. Changes in survival among people with AIDS in Lazio, Italy from 1993 to 1998. AIDS, 1999 13: 2125-2131.</p> <p>Rapiti E., Porta D., Forastiere F., Fusco D., Perucci C.A. for the Lazio AIDS Surveillance Collaborative Group. Socioeconomic status and survival of persons with AIDS before and after the introduction of highly active antiretroviral therapy. Epidemiology 2000; 11:496-501.)</p> <p><b>Other research activity were on HIV post exposure prophylaxis collaborating with “Italian registry of post exposure prophylaxis” and model of care for people with AIDS (Gruppo Romano per i trattamenti a domicilio)</b></p> <p>Puro V., Soldani F., De Carli G., Lazarevic Z., Mattioli F., and Ippolito G. on behalf of the Italian Registry of antiretroviral post-exposure prophylaxis. Drug induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis. AIDS 17: 1987 2003.</p> <p>Orchi N., Girardi E., Antonucci G., Nurra G., Perucci C.A. and Ippolito G. for the Gruppo Romano per i trattamenti a domicilio. AIDS Patient Care and STDs 15: 625-632, 2001</p> |
| <b>Palliative Care and Quality of life in HIV</b> | <p><b>Several studies were carried out on the field of palliative care in HIV in the pre-HAART era. The main field of interest were represented by symptom profile in AIDS, pain in HIV, terminal care</b></p> <p>Fantoni M, Ricci F, Del Borgo C, Izzi I, Damiano F, Moscati AM, Marasca G, Bevilacqua N, Del Forno A. Multicentre study on the prevalence of symptoms and symptomatic treatment in HIV infection. Central Italy PRESINT Group. J Palliat Care. 1997 Summer;13(2):9-13.</p> <p>Fantoni M, Ricci F, Del Borgo C, Bevilacqua N, Izzi I, Damiano F, Marasca G. Symptom profile in terminally ill AIDS patients. AIDS Patient Care STDs. 1996 Jun;10(3):171-3.</p> <p><b>I collaborated as main investigator in Quality of life research group in HIV disease (Istituto superiore di Sanità)</b></p> <p>Bucciardini R, Murri R, Guarinieri M, Starace F, Martini M, Vatrella A, Cafaro L, Fantoni M, Grisetti R, Monforte Ad, Fragola V, Arcieri R, Del Borgo C, Tramarin A, Massella M, Lorenzetti D, Vella S.</p> <p>ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era. Qual Life Res. 2006 Apr;15(3):377-90. .</p> <p>Murri R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O, Wu AW. Determinants of health-related quality of life in HIV-infected patients. AIDS Care. 2003 Aug;15(4):581-90.</p>                                                                                                                                             |

|                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>HIV clinical research</b> | <p><b>I collaborated as main investigator in many clinical studies and research projects, especially in cancers and HIV and antiretroviral therapy</b></p> <p>Ammassari A, Scoppettuolo G, Murri R, Pezzotti P, Cingolani A, Del Borgo C, De Luca A, Antinori A, Ortona L. Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):365-71.</p> <p>Murri R, Fantoni M, Del Borgo C, Izzi I, Visonà R, Suter F, Banfi MC, Barchi E, Orchi N, Bosco O, Wu AW. Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):461-6.</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Hepatitis</b>             | <p><b>Studies were carried out on HBV and HCV, in particular on clinical and virological aspects</b> Tieghi T.Marocco R.Belvisi V.Del Borgo C.Savinelli S.Lichtner M.Mastroianni C.M. Legionella pneumophila pneumonia during telaprevir-based triple therapy for HCV chronic hepatitis. Infection , 42, 1, 225 – 226, 2014</p> <p>Mastroianni C.M, Lichtner, M, Citton R, Del Borgo, Cosmo, Rago A, Martini H, Cimino, Giuseppe, Vullo V Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World Journal of gastroenterology, 3881 – 3887, 2011</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>SARS-COV 2</b>            | <p><b>During the current pandemy, I conducted and participated clinical and experimental studies in patients affected by SARS- CoV2 infection. The main interest on filed was the antiviral therapy. Del Borgo C, Garattini S, Bortignon C, et al D'Onofrio O, Bagagli G, Bonanni G, Zuccalà P, Fabietti P, Tortellini E, Guardiani M, Spagnoli A, Marocco R, Alunni Fegatelli D, Lichtner M Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use. Viruses. 2023 Apr 21;15(4):1025.</b></p> <p><b>Several studies was focused on the identification of the risk factors for the severe form in the context of metabolic comorbidities, such as diabetes, metabolic syndrome and cardiovascular events</b> (Maddaloni E, D'Onofrio L, Alessandri F, et al for CoViDiab Study Group. Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol. 2020 Oct 1;19(1):164.).</p> <p><b>Regarding therapy we studied the effect of immunomodulators agents such us tocilizumab and steroids and many studies were conducted on the immunological pattern of COVID-19 patients Other projects are ongoing, on the specific immune response in frail SARS-CoV2 vaccinated subjects.</b></p> <p><b>Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia.</b> Zingaropoli MA, Latronico T, Pasculli P, Masci GM, Merz R, Ciccone F, Dominelli F, Del Borgo C et al. Biomolecules. 2023 Jun 26;13(7):1040.</p> <p>Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. Marocco R, Carraro A, Zingaropoli MA, Nijhawan P, Tortellini E, Guardiani M, Mengoni F, Zuccalà P, Belvisi V, Kertusha B, Parente A, Del Borgo C, Vullo V, Ciardi MR, Mastroianni CM, Lichtner M. Front Immunol. 2022 Apr 4;13:871592.</p> <p><b>Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients.</b> Guardiani M, Zingaropoli MA, Cogliati Dezza F,</p> |

|                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                      | <p>Centofanti A, Carillo C, Tortellini E, Dominelli F, Napoli A, Del Borgo C, et al. Vaccines (Basel). 2022 Sep 30;10(10):1642.</p> <p><b>Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia.</b> Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccalà P, Perri V, Marocco R, Kertusha B, Siccardi G, Del Borgo C, et al Front Immunol. 2021 Feb 26.</p> <p><b>Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate to-severe COVID-19 pneumonia: a retrospective cohort study</b> Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.</p> <p>Russo G, Solimini A, Zuccalà P, Zingaropoli MA, Carraro A, Pasculli P, Perri V, Marocco R, Kertusha B, Del Borgo C, et al. PLoS One. 2021 Sep 10;16.</p>                                                                                                                                                                                                                                                                                                         |
| <b>Healthcare-associated infection and infection control studies</b> | <p><b>Studies on effective approaches in contrasting nosocomial infections in particular KPC spreading in the hospital focusing on ICU, haematology and neurosurgery wards.</b> Bibbolino G, Di Lella FM, Oliva A, Lichtner M, Del Borgo C, et al. Molecular epidemiology of NDM-5-producing Escherichia coli high-risk clones identified in two Italian hospitals in 2017-2019. Diagn Microbiol Infect Dis. 2021, Aug;100(4):115399.</p> <p><b>Impact of SARS CoV-2 pandemic on carbapenemase-producing Klebsiella pneumoniae prevention and control programme: convergent or divergent action?</b></p> <p>Belvisi V, Del Borgo C, et al. J Hosp Infect. 2021 Mar; 109:29-31.</p> <p>Main Referent of AUSL Latina for the Multicentric Study: <b>INSIEME (Coordinator Centre, Department of Infectious Diseases University of Modena)</b></p> <p><b>Other clinical studies and research projects were performed on surgical infections</b></p> <p>Ferraro F, Piselli P, Pittalis S, Ruscitti LE, Cimaglia C, Ippolito G, Puro V; Centro di Riferimento per le Infezioni associate alle Pratiche Assistenziali Latium Region Group.</p> <p><b>Surgical site infection after caesarean section: space for post-discharge surveillance improvements and reliable comparisons.</b> New Microbiol. 2016 Apr;39(2):134-8.</p> |
| <b>Antibiotic stewardship</b>                                        | <p><b>Main referent of AUSL Latina for “Piano Nazionale di Contrasto dell’Antimicrobico-Resistenza (PNCAR) 2022-2025”.</b></p> <p><b>Main investigator for AUSL Latina: Multicenter study: Antimicrobial stewardship in strutture sanitarie per acuti.</b>( Coordinator centre INMI L. Spallanzani)</p> <p><b>Main Referent of AUSL Latina for the Multicentric Study: RESISTIMIT (Coordinator Centre University of Pisa)</b></p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

Invited speaker at national or international congresses

| Year | Conference                                                                                                                                                                                                     |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1995 | Accessi venosi centrali a lungo termine per nutrizione parenterale e chemioterapia, Roma UCSC, 28 gennaio 1995                                                                                                 |
| 1998 | 5th Annual Meeting of International Society for Quality of life Research, Baltimore 15-17 1998.                                                                                                                |
| 2002 | Nuove Frontiere in Infettivologia, Viterbo 18 ottobre 2002                                                                                                                                                     |
| 2009 | Focus sulle infezioni endoaddominali, Casamari 23 maggio 2009                                                                                                                                                  |
| 2011 | IV Convegno Infettivologico Pontino: LA GESTIONE MULTIDISCIPLINARE DELLE URGENZE INFETTIVOLOGICHE, Aula Palazzina Direzionale, Ospedale Santa Maria Goretti, Latina 23 settembre 2011                          |
| 2009 | Legionella nelle strutture ricettive, prevenzione e gestione del rischio, Latina 3 ottobre 2009                                                                                                                |
| 2010 | Focus sulle infezioni da Gram-positivi. Casamari, 22 maggio 2010                                                                                                                                               |
| 2010 | Accessi Vascolari: Impianto ed utilizzo dei cateteri venosi centrali, Prevenzione, diagnosi e terapia delle complicanze infettive, Aula Magna, Padiglione Oncologico “Giorgio Porfiri”, Latina 22 gennaio 2010 |
| 2011 | Questioni aperte in HIV, Latina, Foro Appio , 8 giugno 2011.                                                                                                                                                   |
| 2012 | Infettivologo in Tour: Infettivologo e Rianimatore: due ruoli a confronto, 13 aprile 2012. Ospedale S. M. Goretti                                                                                              |
| 2012 | Il linfedema post-mastectomia: il trattamento dell’arto superiore: AUSL Latina 8/6/2012.                                                                                                                       |
| 2012 | Workshop GISIG (gruppo italiano di studio sulle infezioni gravi) Roma 14 novembre 2012.                                                                                                                        |
| 2013 | Cost effective initiatives: expert meeting 2013: procedure di prevenzione delle Infezioni ospedaliere: ospedale di Latina, 18 giugno 2013.                                                                     |
| 2013 | Infezioni gravi: la riscossa dei nuovi beta-lattamici. Roma 13 dicembre 2013.                                                                                                                                  |
| 2013 | BE-LINK-percorso intraospedaliero sull’epatite B, Latina 27 giugno 2013.                                                                                                                                       |
| 2014 | Percorso diagnostico-terapeutico nella gestione del paziente critico. Roma 4 giugno 2014                                                                                                                       |

|      |                                                                                                                                                                  |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2014 | Giornata di aggiornamento professionale sul management degli accessi vascolari, Ospedale S. Maria Goretti, 27 giugno 2014, Latina.                               |
| 2016 | Il paziente con infezioni polimicrobiche, quali problematiche nell'era dei germi MDR?. Latina, Foro Appio, 22 ottobre 2016.                                      |
| 2017 | Gestione ed assistenza delle lesioni attraverso la terapia topica a pressione negativa-VAC therapy; 24 maggio 2017, Università La Sapienza, Roma sede di Latina. |
| 2017 | L'appropriatezza prescrittiva antibiotica , Latina, Ospedale S. M. Goretti 23 ottobre 2017                                                                       |
| 2017 | VI Congresso Nazionale SIMIT, Salerno 15-18 ottobre 2017.                                                                                                        |
| 2017 | Fadoi "Aggiornamenti in Medicina interna": Latina, 23 settembre 2017,                                                                                            |
| 2018 | Ideal Debates, Latina, Ospedale S. M. Goretti, 16 marzo 2018.                                                                                                    |
| 2018 | Infezioni nosocomiali correlate all'assistenza e antibioticotterapia long-acting nelle infezioni Gram+, Latina, Ospedale S. M Goretti 26 marzo 2018.             |
| 2018 | Aggiornamenti in Medicina Interna: La multidisciplinarietà nella complessità delle infezioni, esperienze a confronto, Latina, 12 ottobre 2018.                   |
| 2018 | Congresso Nazionale SIMIT, Torino 2-5 dicembre 2018                                                                                                              |
| 2019 | Infezioni gravi nel paziente complesso, Ospedale S. Maria Goretti, Latina 22 febbraio 2019.                                                                      |
| 2019 | Il ruolo della fosfomicina e.v., Sapienza Università di Roma, sede di Latina, 12 marzo 2019                                                                      |
| 2019 | Congresso Regionale Lazio SIMG (Società Italiana di Medicina Generale e delle Cure Primarie), Roma 21 settembre 2019.                                            |
| 2019 | "Obiettivo Eradicazione HCV e Prevenzione HIV nel singolo e nella collettività", Latina 19 dicembre 2019                                                         |
| 2020 | Antibioticoresistenza dell'uomo e nell'animale" presso la sede Cersites di Latina in data 26/9/2020                                                              |
| 2021 | Convegno Simit Regionale Lazio, Latina 29/10/2021, Sessione III                                                                                                  |

|      |                                                                                                                                                                                                                |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2021 | Convegno ICAR 2021: Real life use of the anti-SARS CoV-2 monoclonal antibodies in the early phase of infection: planning, enrollment, administration and monitoring.                                           |
| 2022 | ICAR 2022, Bergamo: Short course remdesivir in early Covid-19 as an effective and useful option in both out- and in-patients                                                                                   |
| 2022 | SIMIT 2022 oral communication: impatto di un servizio di consulenza infettivologica attiva (scia) nell'ambito degli interventi di antibiotic stewardship nel contrasto alle infezioni da germi multiresistenti |
| 2022 | SESSIONE MEET THE EXPERT, Le febbri di origine sconosciuta<br>XXI SIMIT, Roma 20-23 novembre 2022 (C061)                                                                                                       |
| 2023 | Opinioni ed evidenze Primo Congresso Gisa Regione Lazio, Roma 9, giugno 2023                                                                                                                                   |
| 2023 | Vaccino anti-Covid-19 fra benefici ed effetti avversi. L'esperienza pontina. Focus su paziente oncologico. Fondi , Castello Caetani, 23 giugno 2023.                                                           |
| 2023 | Convegno Antimicrobico resistenza: la lotta ai super batteri One Health, test di resistenza e nuove terapie. Latina, Ordine dei Medici, 24 giugno 2023                                                         |
| 2023 | IX workshop epato-infettivologico: l'era degli antivirali in ambito epato-infettivologico: impatto clinico, efficacia e nuove prospettive                                                                      |
| 2023 | Congresso regionale SIMIT 2023, Rieti 29 settembre, 2023                                                                                                                                                       |
| 2023 | “Infection-La gestione razionale degli antibiotici in ospedale dalla teoria alla pratica clinica”                                                                                                              |
| 2024 | Sars-COV2: la nuova realtà tra territorio ed ospedale. Vaccinazione e terapie al giorno d'oggi.                                                                                                                |
| 2024 | L'ottimizzazione del percorso terapeutico del paziente con infezioni della cute e dei tessuti molli (ABSSSI)                                                                                                   |

#### Organization of conferences and courses

| Year | Conference/Course                                                                                                |
|------|------------------------------------------------------------------------------------------------------------------|
| 1993 | Le cure palliative per il malato di AIDS. Roma , Università Cattolica del Sacro Cuore, Roma , 14-15 gennaio 1993 |

|                           |                                                                                                                                                                            |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1997                      | “Giornata di studio: Qualità della vita e malattia da HIV”, Roma Università Cattolica del Sacro Cuore, 28 novembre 1997                                                    |
| 2000                      | L’infezione da HIV: epidemiologia, clinica e prevenzione”, Policlinico Gemelli, UCSC, 14-16 novembre 2000.                                                                 |
| 2000                      | Infezione da HIV in odontoiatria”, Roma, Policlinico Gemelli, 21 marzo 2000.                                                                                               |
| 2008-2016 (nine editions) | Convegno Infettivologico Pontino: Aula Palazzina Direzionale, Ospedale Santa Maria Goretti,                                                                                |
| 2015                      | “ La prevenzione delle infezioni nei servizi di diagnosi e cura”, Ospedale S. Maria Goretti, prima edizione 14 dicembre 2015                                               |
| 2015                      | Course:“ Le infezioni nosocomiali: Malattie Infettive emergenti e riemergenti: prevenzione e controllo in ambito ospedaliero”, Ospedale S. Maria Goretti, 20 novembre 2015 |
| 2019                      | Course: “ La prevenzione della Infezioni nei servizi di diagnosi e cura” seconda edizione                                                                                  |
| 2019                      | Course: Controllo della diffusione dei germi multiresistenti: dalla teoria alla pratica”, Latina Ospedale S. M. Goretti 13 giugno 2019                                     |
| 2019                      | Course: Aggiornamento mirato all’approfondimento dell’antibiotico resistenza, Ordine Medici di Latina, Latina 22 giugno 2019                                               |
| 2019                      | Ulcere degli arti inferiori. Approccio multidisciplinare, Ordine Medici di Latina, Latina 7 dicembre 2019.                                                                 |
| 2022                      | L’azienda si struttura : Verso un PDTA sepsi” . Ottobre dicembre 2022. Azienda Ausl Latina , Palazzina direzionale                                                         |
| 2022                      | Scientific secretariat board member: Convegno regionale Simit Lazio 2022, Latina                                                                                           |
| 2023                      | Scientific secretariat board member: Convegno regionale Simit Lazio 2023, Latina                                                                                           |
| 2023                      | Scientific secretariat board member : Congresso nazionale Simit 2023                                                                                                       |

## Part VIII- Social Activities (third mission)

|              |                                                                                                                                                          |                                                                                                                                                                                                                             |
|--------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1991         | Home care program care for person with AIDS (support for direct observed therapy and ganciclovir infusion for Cytomegalovirus retinitis AIDS associated) | Caritas Roma                                                                                                                                                                                                                |
| 1994-1997    | HIV prevention                                                                                                                                           | Survey and campaign of sensibilization in secondary schools in Rome                                                                                                                                                         |
| 2000-2002    | HIV prevention in pregnancy                                                                                                                              | Collaboration as main investigator to Sendih study (Studio trasversale multicentrico sulle caratteristiche comportamentali delle persone con nuova diagnosi di HIV) and PAO-D (survey in pregnant women) (INMI Spallanzani) |
| 2006         | Cluster meningitis cases (Latina)                                                                                                                        | Collaborating to network for management of meningitis cluster outbreak in Latina area with data collection, counselling and relationship with media                                                                         |
| 2010-ongoing | World HIV day                                                                                                                                            | Collaboration to the organization of World HIV days (1 <sup>st</sup> . December)                                                                                                                                            |
| 2010-ongoing | HIV prevention promotion                                                                                                                                 | HIV testing activities implementation in several initiatives involving youngs, women, adults, citizen of Latina. Hospital and non hospital activities. Medical students involvement as peers.                               |

|              |                                                                                                         |                                                                                                                                               |
|--------------|---------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| 2014-ongoing | World Hand hygiene day                                                                                  | Promoting sensibilisation to hand care for clean care in hospital and outside hospital in Latina city                                         |
| 2017         | Outbreak management (Chikungunya)                                                                       | Collaborating to network for management of Chikungunya outbreak in Latina area with data collection, counselling and relationship with media  |
|              |                                                                                                         | Network in Hospital for prevention of nosocomial infection                                                                                    |
| 2017-2018    | Organization and direct involvement (as electric bass player) of artistic manifestation for AUSL Latina | To encourage aggregation of health workers                                                                                                    |
| 2018         | Outbreak management tuberculosis (transmission in primary school)                                       | Collaborating to network for management of tuberculosis outbreak in Latina area with data collection, counselling and relationship with media |
| 2019         | Mother to child infections prevention                                                                   | Open day activities during February 2019 with a active offer of complete screening for sexual active women in Latina                          |
| 2019-ongoing | Public support in COVID-19 pandemic                                                                     | TV and newspaper interviews to increase awareness, prevention and vaccination in SARS-CoV emergencies                                         |
| 2020         | HIV prevention                                                                                          | Official Involvement of Latina Municipality in the international network of Fast Track cities                                                 |
| 2021         | HIV prevention and quality of life implementation                                                       | Collaboration to creation of a Check Point activity community based with point of care testing (POCT) and counselling in Latina               |

### Summary of Scientific Achievements

| Product type           | Number | Data Base | Start | End  |
|------------------------|--------|-----------|-------|------|
| Papers (international) | 72     | Scopus    | 1993  | 2024 |
| Papers (national)      | 4      | Scopus    | 1993  | 2024 |
| Books [scientific]     |        |           |       |      |
| Books [teaching]       |        |           |       |      |

|                               |      |                 |          |
|-------------------------------|------|-----------------|----------|
| Total Impact factor           | 294  | Journal reports | Citation |
| Media impact factor           | 3,9  |                 |          |
| ScopusTotal Citations         | 1168 | Scopus          |          |
| Average Citations per Product | 15,3 | Scopus          |          |
| Hirsch (H) index              | 17   | Scopus          |          |
| Normalized H index*           | 0,5  | Scopus          |          |

\*H index divided by the academic seniority.

## Part IX– Selected Publications

### List of the publications selected for the evaluation.

| N | TITLE                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | I.F<br>relative<br>to the<br>publica<br>tion<br>year | Cited<br>by<br>scopus |
|---|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------|
| 1 | <b>Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia.</b> Cozzi-Lepri A, Borghi V, Rotundo S, Mariani B, Ferrari A, <b>Del Borgo C</b> , Bai F, Colletti P, Miraglia P, Torti C, Cattelan AM, Cenderello G, Berruti M, Tascini C, Parruti G, Coladonato S, Gori A, Marchetti G, Lichtner M, Coppola L, Sorace C, D'Abramo A, Mazzotta V, Guaraldi G, Franceschini E, Meschiari M, Sarmati L, Antinori A, Nicastri E, Mussini C. Front Med (Lausanne). 2024 Mar 11;11:1293431. | 3,1                                                  | 0                     |
| 2 | <b>Effectiveness, Tolerability and Prescribing Choice of antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use.</b><br><b>Del Borgo C</b> , Garattini S, Bortignon C, Carraro A, Di Trento D, Gasperin A, Grimaldi A, De Maria SG, Corazza S, Tieghi T, Belvisi V, Kertusha B, De Masi M, D'Onofrio O, Bagagli G, Bonanni G, Zuccalà P, Fabietti P, Tortellini E, Guardiani M, Spagnoli A, Marocco R, Alunni Fegatelli D, Lichtner M, Latina Covid-Group. Viruses. 2023 Apr 21;15(4)             | 3,8                                                  | 8                     |
| 3 | <b>Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves.</b> Marocco R, <b>Del Borgo C</b> , Tortellini E, Garattini S, Carraro A, Di Trento D, Gasperin A, Grimaldi A, Tieghi T, Belvisi V, Kertusha B, Guardiani M, Zuccalà P, Alunni Fegatelli D, Spagnoli A, Lichtner M, Latina Covid-Group. Viruses. 2023 Apr 11;15(4):947.                                                                                                                                                     | 3,8                                                  | 3                     |
| 4 | <b>Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia.</b> Zingaropoli MA, Latronico T, Pasculli P, Masci GM, Merz R, Ciccone F, Dominelli F, <b>Del Borgo C</b> , Lichtner M, Iafrate F, Galardo G, Pugliese F, Panebianco V, Ricci P, Catalano C, Ciardi MR, Liuzzi GM, Mastroianni CM. Biomolecules. 2023 Jun 26;13(7):1040.                                                                                                                                                                              | 4,8                                                  | 4                     |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                            |       |    |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----|
| 5  | <b>Systemic, Mucosal Immune Activation and Psycho-Sexual Health in ART- Suppressed Women Living with HIV: Evaluating Biomarkers and Environmental Stimuli.</b> Nijhawan P, Carraro A, Vita S, <b>Del Borgo C</b> , Tortellini E, Guardiani M, Zingaropoli MA, Mengoni F, Petrozza V, Di Troia L, Marcucci I, Kertusha B, Scerpa MC, Turriziani O, Vullo V, Ciardi MR, Mastroianni CM, Marocco R, Lichtner. Viruses. 2023 Apr 13;15(4):960. | 3,8   | 0  |
| 6  | <b>Longitudinal Virological and Immunological Profile in a Case of Human Monkeypox Infection.</b> Zingaropoli MA, Parente A, Kertusha B, Campagna R, Tieghi T, Garattini S, Marocco R, Carraro A, Tortellini E, Guardiani M, Dominelli F, Turriziani O, Ciardi MR, Mastroianni CM, <b>Del Borgo C</b> , Lichtner M. Open forum Infect Dis. 2022 Nov 1;9(12):ofac569.                                                                       | 4,2   | 4  |
| 7  | <b>Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients.</b> Marocco R, Carraro A, Zingaropoli MA, Nijhawan P, Tortellini E, Guardiani M, Mengoni F, Zuccalà P, Belvisi V, Kertusha B, Parente A, <b>Del Borgo C</b> , Vullo V, Ciardi MR, Mastroianni CM, Lichtner M. Front Immunol. 2022 Apr 4;13:871592.                                                                                     | 7,3   | 3  |
| 8  | <b>Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients.</b> Guardiani M, Zingaropoli MA, Cogliati Dezza F, Centofanti A, Carillo C, Tortellini E, Dominelli F, Napoli A, <b>Del Borgo C</b> , Gaeta A, Venuta F, Vullo V, Lichtner M, Ciardi MR, Mastroianni CM, Russo G. Vaccines (Basel). 2022 Sep 30;10(10):1642. doi: 10.3390/vaccines10101642.                            | 7,8   | 4  |
| 9  | <b>Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia.</b> Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccalà P, Perri V, Marocco R, Kertusha B, Siccardi G, <b>Del Borgo C</b> , Curtolo A, Ajassa C, Iannetta M, Ciardi MR, Mastroianni CM, Lichtner M. Front Immunol. 2021 Feb 26.   | 6,373 | 53 |
| 10 | <b>Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate to-severe COVID-19 pneumonia: a retrospective cohort study Real-life use</b>                                                                                                                                                                                                                                                         | 3,752 | 7  |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                       |       |    |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|----|
|    | <p><b>of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.</b></p> <p>Russo G, Solimini A, Zuccalà P, Zingaropoli MA, Carraro A, Pasculli P, Perri V, Marocco R, Kertusha B, <b>Del Borgo C</b>, Del Giudice E, Fondaco L, Tieghi T, D'Agostino C, Oliva A, Vullo V, Ciardi MR, Mastroianni CM, Lichtner M. PLoS One. 2021 Sep 10;16.</p> |       |    |
| 11 | <p><b>Molecular epidemiology of NDM-5-producing Escherichia coli high-risk clones identified in two Italian hospitals in 2017-2019.</b> Bibbolino G, Di Lella FM, Oliva A, Lichtner M, <b>Del Borgo C</b>, Raponi G, Trancassini M, Mengoni F, Arcari G, Antonelli G, Carattoli A. Diagn Microbiol Infect Dis. 2021 Aug;100(4):115399.</p>                                                                                            | 2,983 | 14 |
| 12 | <p><b>Impact of SARS CoV-2 pandemic on carbapenemase-producing Klebsiella pneumoniae prevention and control programme: convergent or divergent action?</b></p> <p>Belvisi V, <b>Del Borgo C</b>, Vita S, Redaelli P, Dolce P, Pacella D, Kertusha B, Carraro A, Marocco R, De Masi M, Mastroianni C, Lichtner M; IPC Program Working Group. J Hosp Infect. 2021 Mar; 109:29-31.</p>                                                   | 8,944 | 18 |

List of publications in international journals

|    |                                                                                                                                                                                                                                                                                                                              |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1  | Adverse-effects of antibiotics in the elderly   Federico, G.,Del Forno, A., <b>Del Borgo, C.</b> , Lucia, M.B., Giornale di Gerontologia, 1993, 41(11), pp. 481–486 IF 0 cit.0                                                                                                                                               |
| 2  | Acariasis in patients with HIV-infection: Personal case-report Marasca G., <b>Del Borgo C.</b> Ricci F.,Bevilacqua N.,Guerriero G.,Capizzi R. Giornale di Malattie Infettive e Parassitarie Volume 46, Issue 8, Pages 695 – 6981994 IF 0 cit. 0                                                                              |
| 3  | Retinal cotton wool spots in HIV infected patients . Caprilli, A.,Minnella, A.M., <b>Del Borgo, C.</b> ,Fantoni, M Annali di Oftalmologia e Clinica Oculistica, 1994, 120(6), pp. 365–372.IF 0 cit. 0                                                                                                                        |
| 4  | Adverse reactions to sulphonamides in patients with HIV infection. Federico G, Del Forno A, <b>Del Borgo C</b> , Ricci F, Tumbarello M, Fantoni M. J Chemother. 1995 Nov;7 Suppl 4:190-2. PMID: 8904152. IF: 0,665 cit: 0                                                                                                    |
| 5  | Symptom profile in terminally ill AIDS patients. Fantoni M, Ricci F, <b>Del Borgo C</b> , Bevilacqua N, Izzi I, Damiano F, Marasca G. AIDS Patient Care STDS. 1996 Jun;10(3):171-3. IF: 1.303 cit: 16                                                                                                                        |
| 6  | Multicentre study on the prevalence of symptoms and symptomatic treatment in HIV infection. Central Italy PRESINT Group. Fantoni M, Ricci F, <b>Del Borgo C</b> , Izzi I, Damiano F, Moscati AM, Marasca G, Bevilacqua N, Del Forno A J Palliat Care. 1997 Summer;13(2):9-13. PMID: 9231582. IF: 0,8543 cit: 42              |
| 7  | Sinusitis in HIV-infected patients. <b>Del Borgo C</b> , Del Forno A, Ottaviani F, Fantoni M. J Chemother. 1997 Apr;9(2):83-8. IF: 1,136 cit: 16                                                                                                                                                                             |
| 8  | Treatment of human immunodeficiency virus-related thrombocytopenia with intravenous anti-rhesus D immunoglobulin. Izzi I, <b>Del Borgo C</b> , Marasca G. Clin Infect Dis. 1997 Jul;25(1):171-2. IF: 2,803 cit: 0                                                                                                            |
| 9  | Changing disease patterns in focal brain lesion-causing disorders in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. Ammassari A, Scoppettuolo G, Murri R, Pezzotti P, Cingolani A, <b>Del Borgo C</b> , De Luca A, Antinori A, Ortona L. 1998 Aug 1;18(4):365-71. IF: 4.119 cit: 49                                       |
| 10 | Non-Hodgkin's lymphoma of the maxillary sinus in a patient with acquired immunodeficiency syndrome. Del Forno A, <b>Del Borgo C</b> , Turriziani A, Ottaviani F, Antinori A, Fantoni M. J Laryngol Otol. 1998 Oct;112(10):982-5. IF: 0,433 cit: 2                                                                            |
| 11 | Inter-rater reliability of a modified Karnofsky Scale of Performance Status for HIV-infected individuals. Fantoni M, Izzi I, <b>Del Borgo C</b> , Del Forno A, Damiano F, Pezzotti P, Franzetti M, Negri C, Quirini T, Zambelli A. AIDS Patient Care STDS. 1999 Jan;13(1):23-8. IF: 0,232 cit ;0                             |
| 12 | The symptoms in HIV disease: prevalence and control. Fantoni M., <b>Del Borgo C.</b> , Recenti Prog. Med. 1999 Apr; 90(4):217-21.IF 0 cit.0                                                                                                                                                                                  |
| 13 | Evaluation of the utility of serological tests in the diagnosis of candidemia. Pallavicini F, Izzi I, Pennisi MA, Morace G, Portaccio GG, Bello G, Iodice F, Godino D, <b>Del Borgo C</b> , Proietti R. Minerva Anestesiol. 1999 Sep;65(9):637-9. PMID: 10522134. IF: 1,6627 cit: 11                                         |
| 14 | Psychological discomfort and mental illness in patients with AIDS: implications for home care. Pozzi G, <b>Del Borgo C</b> , Del Forno A, Genualdo A, Mannelli P, Fantoni M. AIDS Patient Care STDS. 1999 Sep;13(9):555-64. IF: 0,232 cit: 6                                                                                 |
| 15 | Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. Murri R, Fantoni M, <b>Del Borgo C</b> , Izzi I, Visonà R, Suter F, Banfi MC, Barchi E, Orchi N, Bosco O, Wu AW . J Acquir Immune Defic Syndr. 1999 Dec 15;22(5):461-6.IF: 4,407 cit 34 |
| 16 | Multidimensional aspects of pain in HIV-infected individuals. <b>Del Borgo C</b> , Izzi I, Chiarotti F, Del Forno A, Moscati AM, Cornacchione E, Fantoni M AIDS Patient Care STDS. 2001 Feb;15(2):95-102. IF: 0,517 cit 48                                                                                                   |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 17 | Italian Registry of Antiretroviral Post-Exposure Prophylaxis. Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. Puro V, De Carli G, Orchi N, Palvarini L, Chiodera A, Fantoni M, <b>Del Borgo C</b> , Iemoli E, Niero F, Monti M, Micheloni G, Caggese L, Lodesani C, Raineri G, Massari M, Drenaggi D, Ippolito G; J Biol Regul Homeost Agents. 2001 Jul- Sep;15(3):238-42. PMID: 11693431. IF: 0.71 Cit 22 |
| 18 | Home care for persons with Aids: a case-control study to identify determinants of referral to a hospital-based scheme. Antonucci G, Girardi E, Orchi N, Perucci CA, Fantoni M, Aloisi MS, <b>Del Borgo C</b> , Turbessi G, Macedonio A, Ippolito G. J Biol Regul Homeost Agents. 2001 Jul-Sep;15(3):322-8. PMID: 11693444 IF: 0,71 cit: 1                                                                                                                   |
| 19 | Drugs and cardiotoxicity in HIV and AIDS. Fantoni M, Autore C, <b>Del Borgo C</b> . Ann.N.Y. Acad Sci. 2001 Nov; 946:179-99 IF: 1,614 cit 58                                                                                                                                                                                                                                                                                                                |
| 20 | Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents. Fantoni M, <b>Del Borgo C</b> , Autore C, Barbaro G. Ital Heart J. 2002 May;3(5):294-9. PMID: 12066561. IF: 0,205 cit 13                                                                                                                                                                                                                           |
| 21 | Determinants of health-related quality of life in HIV-infected patients. Murri R, Fantoni M, <b>Del Borgo C</b> , Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O, Wu AW. AIDS Care. 2003 Aug;15(4):581-90. IF: 1.19 cit: 97                                                                                                                                                                                                           |
| 22 | Evaluation and management of metabolic and coagulative disorders in HIV-infected patients receiving highly active antiretroviral therapy. Fantoni M, <b>Del Borgo C</b> , Autore C. AIDS. 2003 Apr;17 Suppl 1:S162-9. IF: 5,521 cit: 27                                                                                                                                                                                                                     |
| 23 | Nonnucleoside reverse transcriptase inhibitor-containing regimens are associated with increased satisfaction with sexual life. Murri R, Fantoni M, <b>Del Borgo C</b> , Longo B, Deiana G, Visonà R, Zambelli A, Barchi E, Orchi N, Bosco O, Wu AW. J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):532-4. IF: 3,681 cit: 5                                                                                                                                  |
| 24 | Yersinia pseudotuberculosis septicemia and HIV. Paglia MG, D'Arezzo S, Festa A, <b>Del Borgo C</b> , Loiacono L, Antinori A, Antonucci G, Visca P. Emerg Infect Dis. 2005 Jul;11(7):1128-30. IF: 5,308 cit 13                                                                                                                                                                                                                                               |
| 25 | ISSQoL: a new questionnaire for evaluating the quality of life of people living with HIV in the HAART era. Bucciardini R, Murri R, Guarinieri M, Starace F, Martini M, Vatrella A, Cafaro L, Fantoni M, Grisetti R, Monforte Ad, Fragola V, Arcieri R, <b>Del Borgo C</b> , Tramarin A, Massella M, Lorenzetti D, Vella S. Qual Life Res. 2006 Apr;15(3):377-90. IF: 2037 cit 21                                                                            |
| 26 | A case of acute polyradiculoneuropathy, drug-induced hypersensitivity, and HHV-6 infection. <b>Del Borgo C</b> , Zaniratti S, Minosse C, Vetica A, Bellini A, Soscia F, Missori P, Pierelli F, Currà A. Neurology. 2009 Mar 10;72(10):935-6. IF: 8,172 cit: 3                                                                                                                                                                                               |
| 27 | In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, Marocco R, <b>Del Borgo C</b> , Soscia F, Vullo V, Mastroianni CM. PLoS One. 2009;4(4):e5187. IF: 4,351 cit: 46                                                                                                                                                          |
| 28 | Case 11-2009: a man with fever, headache, rash, and vomiting. <b>Del Borgo C</b> , Soscia F, Mastroianni CM. N Engl J Med. 2009 Jul 16;361(3):312-3; author reply 313-4. IF: 47,05 cit: 0                                                                                                                                                                                                                                                                   |
| 29 | Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report. Belvisi V, Fabietti P, <b>Del Borgo C</b> , Marocco R, DI Vincenzo E, Soscia F, Mastroianni CM. J Chemother. 2009 Jun;21(3):367-8. IF: 1,166 cit 7                                                                                                                                                                                              |
| 30 | Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Rago A, Lichtner M, Mecarocci S, Marocco R, Cenfra N, Belvisi V, <b>Del Borgo C</b> , Cimino G, Mastroianni CM. Antivir Ther. 2010;15(6):929-32. IF: 3,774 cit: 18                                                                                                                                                     |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31 | Diagnostic and therapeutic approach in a rare case of primary bilateral adrenal tuberculosis. <b>Del Borgo C</b> , Urigo C, Marocco R, Belvisi V, Pisani L, Citton R, Cianni R, Soscia F, Lichtner M, Mastroianni CM. J Med Microbiol. 2010 Dec;59(Pt 12):1527-1529. IF: 2,338 cit: 4                                                                                                                               |
| 32 | Pulmonary embolism and acute cytomegalovirus infection in an immunocompetent patient. <b>Del Borgo C</b> , Gianfreda R, Belvisi V, Citton R, Soscia F, Notarianni E, Tieghi T, Mastroianni CM. Infez Med. 2010 Dec;18(4):270-2. PMID: 21196823. IF: 0 cit 3                                                                                                                                                         |
| 33 | Current trends in management of hepatitis B virus reactivation in the biologic therapy era. : Mastroianni CM, Lichtner M, Citton R, <b>Del Borgo C</b> , Rago A, Martini H, Cimino G, Vullo V. World J Gastroenterol. 2011 Sep 14;17(34):3881-7. IF: 2,471 cit 51                                                                                                                                                   |
| 34 | Severe and persistent depletion of circulating plasmacytoid dendritic cells in patients with 2009 pandemic H1N1 infection. Lichtner M, Mastroianni CM, Rossi R, Russo G, Belvisi V, Marocco R, Mascia C, <b>Del Borgo C</b> , Mengoni F, Sauzullo I, D'Ettorre G, D'Agostino C, Massetti AP, Vullo V. PLoS One. 2011;6(5):e19872. IF: 4,092 cit 29                                                                  |
| 35 | Pandemic influenza H1N1, legionellosis, splenic rupture, and vascular thrombosis: a dangerous cocktail. Citton R, <b>Del Borgo C</b> , Belvisi V, Mastroianni CM. J Postgrad Med. 2012 Jul-Sep;58(3):228-9. IF: 1,078 cit: 7                                                                                                                                                                                        |
| 36 | Bartonella henselae infection presenting with ocular and hepatosplenic manifestations in an immunocompetent child. Belvisi V, Tieghi T, Grenga PL, Marocco R, Vetica A, <b>Del Borgo C</b> , Citton R, Lichtner M, Mastroianni CM. Pediatr Infect Dis J. 2012 Aug;31(8):882-3. IF: 3,569 cit 3                                                                                                                      |
| 37 | Late onset invasive pneumococcal disease in a liver transplanted patient: beyond the Austrian syndrome. Belvisi V, <b>Del Borgo C</b> , Morelli F, Marocco R, Tieghi T, Fabietti P, Vetica A, Lichtner M, Mastroianni CM. Transpl Infect Dis. 2013 Jun;15(3):E111-4. IF: 2,25 cit: 12                                                                                                                               |
| 38 | Postpartum fever in the presence of a fibroid: Sphingomonas paucimobilis sepsis associated with pyomyoma. <b>Del Borgo C</b> , Maneschi F, Belvisi V, Morelli F, Vetica A, Marocco R, Tieghi T, Lichtner M, Mastroianni CM. BMC Infect Dis. 2013 Dec 5;13:574. IF: 2,561 cit: 14                                                                                                                                    |
| 39 | Legionella pneumophila pneumonia during telaprevir-based triple therapy for HCV chronic hepatitis. Tieghi T, Marocco R, Belvisi V, <b>Del Borgo C</b> , Savinelli S, Lichtner M, Mastroianni CM. Infection. 2014 Feb;42(1):225-6. IF: 2,618 cit: 0                                                                                                                                                                  |
| 40 | Atypical presentation of crusted (Norwegian) scabies. <b>Del Borgo C</b> , Belvisi V, Tieghi T, Mastroianni CM. Infection. 2015 Oct;43(5):623-4. IF: 2,294 cit: 10                                                                                                                                                                                                                                                  |
| 41 | Large Nosocomial Outbreak Associated with a Norwegian Scabies Index Case Undergoing TNF- $\alpha$ Inhibitor Treatment: Management and Control. Belvisi V, Orsi GB, <b>Del Borgo C</b> , Fabietti P, Ianari A, Albertoni F, Porcelli P, Potenza C, Mastroianni CM. Infect Control Hosp Epidemiol. 2015 Nov;36(11):1358-60. IF: 3,669 cit: 16                                                                         |
| 42 | Surgical site infection after caesarean section: space for post-discharge surveillance improvements and reliable comparisons. Ferraro F, Piselli P, Pittalis S, Ruscitti LE, Cimaglia C, Ippolito G, Puro V; Centro di Riferimento per le Infezioni associate alle Pratiche Assistenziali Latium Region Group (tra cui <b>C. Del Borgo</b> ). New Microbiol. 2016 Apr;39(2):134-8. PMID: 27196552. IF: 1,568 cit 15 |
| 43 | Diplopia as isolated presentation of varicella zoster central nervous system reactivation. <b>Del Borgo C</b> , Belvisi V, Valli MB, Currà A, Pozzetto I, Sepe M, Mastroianni CM. J Neurovirol. 2017 Aug;23(4):621-624. IF: 3,228 cit 1                                                                                                                                                                             |
| 44 | Case report: human papilloma virus type 120-related papillomatosis mimicking laryngeal carcinoma. Belvisi V, Martellucci S, Garbuglia AR, <b>Del Borgo C</b> , Martellucci S, Baiocchi A, Manicone AM, Bagni O, Mastroianni CM, Gallo A. Infection. 2017 Oct;45(5):709-713. IF: 2,773 cit: 1                                                                                                                        |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 45 | Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study. Lanini S, Scognamiglio P, Mecozzi A, Lombardozzi L, Vullo V, Angelico M, Gasbarrini A, Taliani G, Attili AF, Perno CF, De Santis A, Puro V, Cerqua F, D'Offizi G, Pellicelli A, Armignacco O, Mennini FS, Siciliano M, Girardi E, Panella V, Ippolito G; members of the Lazio Region HCV treatment group ( <b>tra cui C. Del Borgo</b> ). BMC Infect Dis. 2018 May 16;18(1):223. IF: 2,565 cit 19                                                                                                                                                               |
| 46 | Persistent high plasma levels of sCD163 and sCD14 in adult patients with measles virus infection. Mascia C, Pozzetto I, Kertusha B, Marocco R, <b>Del Borgo C</b> , Tieghi T, Vita S, Savinelli S, Iannetta M, Vullo V, Lichtner M, Mastroianni CM. PLoS One. 2018 May 24;13(5):e0198174. IF: 2,776 cit: 9                                                                                                                                                                                                                                                                                                                                                   |
| 47 | Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, ( <b>C. Del Borgo</b> ). J Transl Med. 2020 Oct 21;18(1):405 IF: 5,531 cit: 106 |
| 48 | Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Maddaloni E, D'Onofrio L, Alessandri F, Mignogna C, Leto G, Pascarella G, Mezzaroma I, Lichtner M, Pozzilli P, Agrò FE, Rocco M, Pugliese F, Lenzi A, Holman RR, Mastroianni CM, Buzzetti R; CoViDiab Study Group ( <b>tra cui C. Del Borgo</b> ). Cardiovasc Diabetol. 2020 Oct 1;19(1):164. IF: 9,951 cit: 80                                                                                                                                                                  |
| 49 | Auricle pernio as a manifestation of Covid-19 infection. Proietti I, Tolino E, Bernardini N, Mambrin A, Balduzzi V, Marchesiello A, Michelini S, <b>Del Borgo C</b> , Skroza N, Lichtner M, Potenza C. Dermatol Ther. 2020 Nov;33(6):e14089. IF: 3,264 cit: 5                                                                                                                                                                                                                                                                                                                                                                                                |
| 50 | Neck circumference as reliable predictor of mechanical ventilation support in adult inpatients with COVID-19: A multicentric prospective evaluation. Di Bella S, Cesareo R, De Cristofaro P, Palermo A, Sanson G, Roman-Pognuz E, Zerbato V, Manfrini S, Giacomazzi D, Dal Bo E, Sambataro G, Macchini E, Quintavalle F, Campagna G, Masala R, Ottaviani L, <b>Del Borgo C</b> , Ridola L, Leonetti F, Berlot G, Luzzati R. Diabetes Metab Res Rev. 2021 Jan;37(1):e3354. IF: 5,034 cit: 11                                                                                                                                                                  |
| 51 | Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia. Zingaropoli MA, Nijhawan P, Carraro A, Pasculli P, Zuccalà P, Perri V, Marocco R, Kertusha B, Siccardi G, <b>Del Borgo C</b> , Curtolo A, Ajassa C, Iannetta M, Ciardi MR, Mastroianni CM, Lichtner M. Front Immunol. 2021 Feb 26. IF 6,373 cit. 53                                                                                                                                                                                                           |
| 52 | Molecular epidemiology of NDM-5-producing Escherichia coli high-risk clones identified in two Italian hospitals in 2017-2019. Bibbolino G, Di Lella FM, Oliva A, Lichtner M, <b>Del Borgo C</b> , Raponi G, Trancassini M, Mengoni F, Arcari G, Antonelli G, Carattoli A. Diagn Microbiol Infect Dis. 2021 Aug;100(4):115399. IF 8,944 cit. 18                                                                                                                                                                                                                                                                                                               |
| 53 | Molecular epidemiology of NDM-5-producing Escherichia coli high-risk clones identified in two Italian hospitals in 2017-2019. Bibbolino G, Di Lella FM, Oliva A, Lichtner M, <b>Del Borgo C</b> , Raponi G, Trancassini M, Mengoni F, Arcari G, Antonelli G, Carattoli A. Diagn Microbiol Infect Dis. 2021 Aug;100(4):115399. IF. 2,983 cit. 14                                                                                                                                                                                                                                                                                                              |
| 54 | Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate to-severe COVID-19 pneumonia: a retrospective cohort study Real-life use of                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    | tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study. Russo G, Solimini A, Zuccalà P, Zingaropoli MA, Carraro A, Pasculli P, Perri V, Marocco R, Kertusha B, <b>Del Borgo C</b> , Del Giudice E, Fondaco L, Tieghi T, D'Agostino C, Oliva A, Vullo V, Ciardi MR, Mastroianni CM, Lichtner M. PLoS One. 2021 Sep 10;16. IF 3,752 cit. 7                                                                                                                                                                                                                                                                                       |
| 55 | Radiographers and COVID-19 pneumonia: Diagnostic performance using CO-RADS. Vicini S, Panvini N, Bellini D, Rengo M, Ciotola M, De Vivo M, Gambaretto C, Caldon V, Panno S, <b>Del Borgo C</b> , Carbone I. Radiography (Lond). 2021 Nov;27(4):1078-1084. IF: 1,185 cit 8                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 56 | Blood glucose and epicardial adipose tissue at the hospital admission as possible predictors for COVID-19 severity. Guarisco G, Fasolo M, Capoccia D, Morsello G, Carraro A, Zuccalà P, Marocco R, <b>Del Borgo C</b> , Pelle G, Iannarelli A, Orlando E, Spagnoli A, Carbone I, Lichtner M, Iacobellis G, Leonetti F; COVID-19 Latina Study Group. Endocrine. 2022 Jan;75(1):10-18. IF: 3,7 cit 5                                                                                                                                                                                                                                                                                                                   |
| 57 | Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients. Guardiani M, Zingaropoli MA, Cogliati Dezza F, Centofanti A, Carillo C, Tortellini E, Dominelli F, Napoli A, <b>Del Borgo C</b> , Gaeta A, Venuta F, Vullo V, Lichtner M, Ciardi MR, Mastroianni CM, Russo G. Vaccines (Basel). 2022 Sep 30;10(10):1642. doi: 10.3390/vaccines10101642. IF 7,8 cit. 4                                                                                                                                                                                                                                                                                               |
| 58 | Longitudinal Virological and Immunological Profile in a Case of Human Monkeypox Infection. Zingaropoli MA, Parente A, Kertusha B, Campagna R, Tieghi T, Garattini S, Marocco R, Carraro A, Tortellini E, Guardiani M, Dominelli F, Turriziani O, Ciardi MR, Mastroianni CM, <b>Del Borgo C</b> , Lichtner M. Open forum Infect Dis. 2022 Nov 1;9(12):ofac569. IF: 4,2 cit 4                                                                                                                                                                                                                                                                                                                                          |
| 59 | Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. Marocco R, Carraro A, Zingaropoli MA, Nijhawan P, Tortellini E, Guardiani M, Mengoni F, Zuccalà P, Belvisi V, Kertusha B, Parente A, <b>Del Borgo C</b> , Vullo V, Ciardi MR, Mastroianni CM, Lichtner M. Front Immunol. 2022 Apr 4;13:871592. IF 7,3 cit.3                                                                                                                                                                                                                                                                                                                                                         |
| 60 | Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH. Tortellini E, Zingaropoli MA, Mancarella G, Marocco R, Carraro A, Jamhour M, Barbato C, Guardiani M, Dominelli F, Pasculli P, Napoli A, Gaeta A, Mengoni F, Zuccalà P, Belvisi V, Kertusha B, Parente A, <b>Del Borgo C</b> , Vullo V, Ciardi MR, Mastroianni CM, Lichtner M, Latina Covid-Group. Int J Mol Sci. 2022 Nov 30;23(23):14988. IF: 5,6 cit: 8                                                                                                                                                                                                                                                                                 |
| 61 | A case of primary central nervous system lymphoma in advanced naive HIV-infected patient: the role of antiviral agents. Carraro A, Belvisi V, Garattini S, Cacace S, Marocco R, <b>Del Borgo C</b> , Fiorentino F, Perrone S, Cimino G, Lichtner M. AIDS. 2022 Nov 1;36(13):1895-1896. IF: 3,8 cit 0                                                                                                                                                                                                                                                                                                                                                                                                                 |
| 62 | Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study). Mastroianni I, Gagliardini R, Segala FV, Mondì A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastrì E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group ( <b>tra cui C. Del Borgo</b> ) EClinicalMedicine. 2023 Mar 10;57:101895. IF: 9,6 cit 1 |
| 63 | Use of Remdesivir in Patients with SARS-CoV-2 Pneumonia in a Real-Life Setting during the Second and Third COVID-19 Epidemic Waves. Marocco R, <b>Del Borgo C</b> ,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    | Tortellini E, Garattini S, Carraro A, Di Trento D, Gasperin A, Grimaldi A, Tieghi T, Belvisi V, Kertusha B, Guardiani M, Zuccalà P, Alunni Fegatelli D, Spagnoli A, Lichtner M, Latina Covid-Group. <i>Viruses</i> . 2023 Apr 11;15(4):947 IF 3,8 cit. 3                                                                                                                                                                                                                                                                                                                              |
| 64 | Effectiveness, Tolerability and Prescribing Choice of antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use.<br><b>Del Borgo C</b> , Garattini S, Bortignon C, Carraro A, Di Trento D, Gasperin A, Grimaldi A, De Maria SG, Corazza S, Tieghi T, Belvisi V, Kertusha B, De Masi M, D'Onofrio O, Bagagli G, Bonanni G, Zuccalà P, Fabietti P, Tortellini E, Guardiani M, Spagnoli A, Marocco R, Alunni Fegatelli D, Lichtner M, Latina Covid-Group. <i>Viruses</i> . 2023 Apr 21;15(4) IF 3,8 cit. 8                 |
| 65 | Association between PaO <sub>2</sub> > FiO <sub>2</sub> ratio and thrombotic events in COVID-19 patients. Loffredo L, Pignatelli P, Pirro M, Ceccarelli G, Oliva A, Maggio E, Cancelli F, D'Ardes D, Amitrano M, Zicari AM, Cinicola BL, Taliani G, Cangemi R, Lichtner M, Falcone M, Orlando F, Pugliese F, Venditti M, Mastroianni CM, Violi F; COVID-Group. <i>Intern Emerg Med</i> . 2023 Apr;18(3):889-895. IF: 3,2 cit: 1                                                                                                                                                       |
| 66 | Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk. : Zingaropoli MA, Pasculli P, Tartaglia M, Dominelli F, Ciccone F, Taglietti A, Perri V, Malimpensa L, Ferrazzano G, Iannetta M, <b>Del Borgo C</b> , Lichtner M, Mastroianni CM, Conte A, Ciardi MR. <i>Biology (Basel)</i> . 2023 Apr 12;12(4):587. IF: 3,6 cit: 2                                                                                                                                                                                                                             |
| 67 | Antibodies in Pregnant Women Infected by COVID-19: A Case Series. Crispino P, Marocco R, Di Trento D, Guarisco G, Kertusha B, Carraro A, Corazza S, Pane C, Di Troia L, <b>Del Borgo C</b> , Lichtner M. <i>Microorganisms</i> . 2023 Jul 31;11(8):1953. IF: 4,1 cit: 1                                                                                                                                                                                                                                                                                                               |
| 68 | TB specific intracellular cytokines production in Synovial liquid for diagnosis of tuberculous arthritis. Vita S, Mascia C, Kertusha B, Marocco R, Sauzullo I, Mengoni F, Pozzetto I, Scalzi A, Nijhawan P, Savinelli S, Fondaco L, Carraro A, <b>Del Borgo C</b> , Mastroianni CM, Lichtner M. <i>J Infect Dev Ctries</i> . 2023 Dec 31;17(12):1829-1833. IF: 1,4 cit 0                                                                                                                                                                                                              |
| 69 | Dysregulated Inflammatory Cytokine Levels May Be Useful Markers in a Better Updated Management of COVID-19.: Iuliano M, Mongiovì RM, Parente A, Kertusha B, Carraro A, Marocco R, Mancarella G, <b>Del Borgo C</b> , Fondaco L, Grimaldi L, Dorrucchi M, Lichtner M, Mangino G, Romeo G. <i>Curr Issues Mol Biol</i> . 2024 Aug 15;46(8):8890-8902. IF: 2,8 cit:0                                                                                                                                                                                                                     |
| 70 | Italian HIV Drug Resistance Group. HIV-1 transmitted drug resistance in newly diagnosed individuals in Italy over the period 2015-21 Fabeni L, Armenia D, Abbate I, Gagliardini R, Mazzotta V, Bertoli A, Gennari W, Forbici F, Berno G, Piermatteo L, Borghi V, Pinnetti C, Vergori A, Mondì A, Parruti G, Di Sora F, Iannetta M, Lichtner M, Latini A, Mussini C, Sarmati L, Perno CF, Girardi E, Antinori A, Ceccherini-Silberstein F, Maggi F, Santoro MM; J Antimicrob Chemother. 2024 Sep 3;79(9):2152-2162. IF: 3,9 cit 0                                                      |
| 71 | Clinical features of patients with type 2 diabetes with and without Covid-19: A case control study (CoViDiab I). Ernesto Maddaloni a, Luca D'Onofrio a, Francesco Alessandri a, Carmen Mignogna a, Gaetano Leto b, Lucia Coraggio a, Sara Sterpetti a, Giuseppe Pascarella c, Ivano Mezzaroma a, Miriam Lichtner b, Paolo Pozzilli c, Felice Eugenio Agro` c, Monica Rocco d, Francesco Pugliese a, Claudio Maria Mastroianni a, Raffaella Buzzetti a,*, the CoViDiab Study group ( <b>tra cui C. Del Borgo</b> ). <i>Diabetes Res Clin Pract</i> 2020 Nov;169:108454 IF 5,602 cit 29 |
| 72 | Longitudinal Assessment of Multiple Immunological and Inflammatory Parameters during Successful DAA Therapy in HCV Monoinfected and HIV/HCV Coinfected Subjects. Zuccalà P, Latronico T, Marocco R, Savinelli S, Vita S, Mengoni F, Tieghi T.,                                                                                                                                                                                                                                                                                                                                        |

|    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|    | <b>Del Borgo C</b> , Kertusha B, D'Ettorre G, Vullo V, Mastroianni C,M , Liuzzi Gm, Lichtner M, Int J Mol Sci . 2022 Oct 8;23(19):11936 IF 5,6 cit 5                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 73 | Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia. Zingaropoli MA, Latronico T, Pasculli P, Masci GM, Merz R, Ciccone F,Dominelli F, <b>Del Borgo C</b> , Lichtner M, Iafrate F, Galardo G, Pugliese F,Panebianco V, Ricci P, Catalano C, Ciardi MR, Liuzzi GM, Mastroianni CM. Biomolecules. 2023 Jun 26;13(7):1040. IF 4,8 cit. 4                                                                                                                                                                             |
| 74 | Systemic, Mucosal Immune Activation and Psycho-Sexual Health in ART- Suppressed Women Living with HIV: Evaluating Biomarkers and Environmental Stimuli. Nijhawan P, Carraro A, Vita S, <b>Del Borgo C</b> , Tortellini E, Guardiani M, Zingaropoli MA, Mengoni F, Petrozza V, Di Troia L, Marcucci I, Kertusha B, Scerpa MC, Turriziani O, Vullo V, Ciardi MR, Mastroianni CM, Marocco R, Lichtner. Viruses. 2023 Apr 13;15(4):960. IF:3,8 cit. 0                                                                                                                      |
| 75 | Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia. Cozzi-Lepri A, Borghi V, Rotundo S, Mariani B, Ferrari A, <b>Del Borgo C</b> , Bai F, Colletti P, Miraglia P, Torti C, Cattelan AM, Cenderello G, Berruti M,Tascini C, Parruti G, Coladonato S, Gori A, Marchetti G, Lichtner M, Coppola L,Sorace C, D'Abramo A, Mazzotta V, Guaraldi G, Franceschini E, Meschiari M,Sarmati L, Antinori A, Nicastrì E, Mussini C. Front Med (Lausanne). 2024 Mar 11;11:1293431. IF 3,1 cit. 0 |
| 76 | Steroid use in measles: A retrospective cohort study during the 2017 outbreak in tertiary referral center, Rome and Latina, Italy. Caraffa E, Mascia C, Ciardi MR, Lichtner M, Ajassa C, <b>Del Borgo C</b> , Tieghi T,Vita S, Savinelli S, Iannetta M, Russo G, Mastroianni CM, Vullo V. J Infect Chemother. 2024 Mar;30(3):201-207 IF 1,9 cit 0                                                                                                                                                                                                                      |

*Cosmo Del Borgo*